Elacestrant(口服选择性雌激素受体降解剂)对比标准内分泌治疗用于雌激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌:随机III期EMERALD试验结果
EMERALD是一项随机、开放标签III期试验,纳入既往接受过1–2线内分泌治疗、需经CDK4/6抑制剂预处理且化疗≤1线的ER阳性/HER2阴性晚期乳腺癌患者,随机接受Elacestrant 400 mg每日一次口服或标准内分泌单药治疗。结果显示,Elacestrant较标准治疗显著延长全体患者及ESR1突变患者的无进展生存期,安全性可控。
要点
- Elacestrant较标准内分泌治疗显著改善全体患者PFS(HR=0.70;95%CI 0.55–0.88;P=.002)。
- ESR1突变患者中Elacestrant的PFS获益更明显(HR=0.55;95%CI 0.39–0.77;P=.0005)。
- 治疗相关3/4级不良事件发生率Elacestrant组7.2% vs 标准治疗组3.1%。
核心结论
- Elacestrant是首个在III期试验中于全体人群及ESR1突变患者中均较标准内分泌治疗显著改善PFS的口服选择性雌激素受体降解剂,安全性可控。
研究设计与样本
- 随机、开放标签、III期EMERALD试验,纳入既往接受1–2线内分泌治疗、需经CDK4/6抑制剂预处理且化疗≤1线的ER阳性/HER2阴性晚期乳腺癌患者。
- 患者随机分配至Elacestrant 400 mg每日一次口服组(n=239)或标准内分泌单药治疗组(n=238)。
- 主要终点为盲法独立中心评审的全体患者及ESR1突变患者的无进展生存期。
主要发现
- 47.8%的患者检出ESR1突变,43.4%的患者接受过两线既往内分泌治疗。
- 全体患者中Elacestrant组PFS较标准治疗组延长(HR=0.70;95%CI 0.55–0.88;P=.002)。
- ESR1突变患者中Elacestrant组PFS较标准治疗组延长(HR=0.55;95%CI 0.39–0.77;P=.0005)。
- 治疗相关3/4级不良事件发生率Elacestrant组为7.2%,标准治疗组为3.1%。
- 因治疗相关不良事件导致停药的比例Elacestrant组为3.4%,标准治疗组为0.9%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with pretreated estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies. METHODS: This randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy. Patients were randomly assigned to elacestrant 400 mg orally once daily or standard-of-care (SOC) endocrine monotherapy. Primary end points were progression-free survival (PFS) by blinded independent central review in all patients and patients with detectable ESR1 mutations. RESULTS: Patients were randomly assigned to elacestrant (n = 239) or SOC (n = 238). ESR1 mutation was detected in 47.8% of patients, and 43.4% received two prior endocrine therapies. PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005). Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0% receiving elacestrant and 18.8% receiving SOC (grade 3/4, 2.5% and 0.9%, respectively). CONCLUSION: Elacestrant is the first oral selective ER degrader demonstrating a significant PFS improvement versus SOC both in the overall population and in patients with ESR1 mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.
引用
- Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022. PMID: 35584336. doi:10.1200/JCO.22.00338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。